Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
NCT04345367
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
727
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Abrocitinib 200 mg
COMBINATION_PRODUCT:
Dupilumab 300 mg
Sponsor
Pfizer